Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

CD19 chimeric antigen receptor (CAR) T-cell therapy has shown great success against B-cell acute lymphoblastic leukemia (B-ALL). Tandem and sequential CD19/CD22 dual-target CAR T-cell therapies have been developed to reduce the possibility of CD19-negative relapse; however, the superior strategy is...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Sining, Zhang, Xinyue, Dai, Haiping, Cui, Wei, Yin, Jia, Li, Zheng, Yang, Xiao, Yang, Chunxiu, Xue, Shengli, Qiu, Huiying, Miao, Miao, Chen, Suning, Jin, Zhengming, Fu, Chengcheng, Li, Caixia, Sun, Aining, Han, Yue, Wang, Ying, Yu, Lei, Wu, Depei, Cui, Qingya, Tang, Xiaowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125987/
https://www.ncbi.nlm.nih.gov/pubmed/37095120
http://dx.doi.org/10.1038/s41408-023-00819-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125987/
https://www.ncbi.nlm.nih.gov/pubmed/37095120
http://dx.doi.org/10.1038/s41408-023-00819-5

Ejemplares similares